Amberstone Biosciences

Solid Tumor Therapies

ABS-102 RD oncology; ABS-110 RD oncology; ABS-280 RD oncology

Amberstone Biosciences aims to create safe and effective immunotherapies. Their T-MATE: Tumor Microenvironment Activated Therapeutics pipeline is made of therapeutic antibodies that target tumors with less off-target damage. Amberstone utilizes their discovery platform, AmberFlow, a high-throughput method to identify novel therapeutic targets via proprietary single-cell microfluidics. AmberFlow’s technology can evaluate candidates quickly, producing high-content information without limitations of molecular format, cell source, or target. Amberstone’s pipeline strategy can target various tumor types and autoimmune diseases.